Robotic Biopsy Devices Market Analysis, Segmentation, Key Players, Opportunities And Forecast 2032
The global Robotic Biopsy Devices Market was valued at US$ 386.4 million in 2021 and is expected to grow at a CAGR of 9.4% during the forecast period (2022-2032). Robotic biopsy systems are the global market leader, with a market share of approximately 59.8% in 2021. By the end of 2032, the global robotic biopsy devices market is expected to be worth approximately US$ 1.1 billion.
One of the most significant cutting-edge technologies in neurosurgery is
robot-assisted biopsy for brain tumors. A robot-assisted biopsy is used to
increase the safety and effectiveness of biopsy technique, which is highly
desired when organizing the management of tumor pathology.
Get a PDF Sample with the Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15412
The main objective of this cutting-edge technology is to add safety
equipment to the modern neurosurgery operative inventory so that it can
methodically improve the precision and accuracy in operation theaters, which is
not otherwise conceivable. Additionally, robotic biopsy makes the thorough
preoperative process easier than other types.
The market for robotic biopsy devices is anticipated to grow at a fast
pace over the projected years due to rising need for safe and effective
minimally invasive procedures and the growing use of automated systems in the
healthcare sector. It can be further attributed to rapid transformation of
conventional healthcare systems to integrated digital technology.
Key Takeaways: Robotic Biopsy Devices Market
- By product, the
systems segment is expected to showcase high growth at a CAGR of 4% by
the end of 2032.
- By application,
the brain biopsy category is leading the global robotic biopsy devices
market and is projected to exhibit a CAGR of 3% during
the forecast period.
- By end user,
hospitals held around 5% of the global robotic biopsy
devices market share in 2021.
- The U.S.
currently dominates the North America robotic biopsy devices
market and it had generated a share of about 8% in 2021.
- The U.K. is set
to hold a share of nearly 2% in the global robotic biopsy
devices market during the assessment period.
"Increasing use of automated technologies for surgical procedures
and growing global burden of chronic diseases are expected to drive sales of
robotic biopsy devices," says an analyst of Future Market Insights.
Gain complete access to the report @ https://www.futuremarketinsights.com/reports/robotic-biopsy-devices-market
Competition Landscape: Robotic Biopsy Devices Market
The market for robotic biopsy devices is oligopolistic, with the presence
of a few established manufacturers. Product range of every player in the market
varies as per the competitors' licensed novel devices with unique applications.
Key players are striving to gain regulatory authorizations for creating new medical
devices, generating high product sales, and initiating marketing purposes.
- In October
2021, Medtronic reported that the Hugo robotic-assisted surgery (RAS)
system had been granted the CE (Conformité Européenne) Mark, allowing for
sales of the system across Europe.
Key Companies Profiled:
- Medtronic
- Renishaw plc
- iSYS
Medizintechnik GmbH
- Mazor Robotics
- Biobot Surgical
Pte Ltd
- Medrobotics
- Medtech SA
Robotic Biopsy Devices Market Outlook by Category
By Product:
- Systems
- Instrument
& Accessories
By Application:
- Brain Biopsy
- Lung Biopsy
- Prostate biopsy
- Other
By End User:
- Hospitals
- Ambulatory
Surgical Centers
- Academic &
Research Institutes
Comments
Post a Comment